Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.
The pharmacokinetics of metronidazole were studied after oral and intravenous administration to seven patients with Crohn's disease and five patients with ulcerative colitis. The oral/intravenous availability ratio was 0.97 +/- 0.2 in the Crohn's patients and 0.90 +/- 0.1 in the colitics (mean +/- s.e. mean). Plasma clearance was 3.24 +/- 0.2 l h-1 and 4.1 +/- 0.5 l h-1, respectively. These differences were not statistically significant. Ten of the patients on long term sulphasalazine were studied to observe the effect of 2 weeks metronidazole therapy on plasma sulphapyridine concentration. The sulphapyridine concentration changed from 22.1 +/- 2.0 micrograms ml-1 to 15.95 +/- 4.5 micrograms ml-1 in the Crohn's patients and 26.0 +/- 6.0 micrograms ml-1 to 36.4 +/- 8.5 micrograms ml-1 in the colitis group, pre- and post-metronidazole. These differences were not statistically significant. These results suggest that metronidazole does not interfere with diazo-link splitting of sulphasalazine and that patients with Crohn's disease handle metronidazole in a similar manner to patients with colitis.
Shaffer
J L
JL
Kershaw
A
A
Houston
J B
JB
D000284:Administration, Oral; D001682:Biological Availability; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000378:metabolism*; D003424:Crohn Disease / Q000188:drug therapy / Q000378:metabolism*; D004341:Drug Evaluation; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000378:metabolism*; D008875:Middle Aged; D012460:Sulfasalazine / Q000008:administration & dosage / Q000378:metabolism*
D008795:Metronidazole; D012460:Sulfasalazine